» Articles » PMID: 32179763

Effect of Induced Hypoglycemia on Inflammation and Oxidative Stress in Type 2 Diabetes and Control Subjects

Overview
Journal Sci Rep
Specialty Science
Date 2020 Mar 18
PMID 32179763
Citations 60
Authors
Affiliations
Soon will be listed here.
Abstract

Intensive diabetes control has been associated with increased mortality in type 2 diabetes (T2DM); this has been suggested to be due to increased hypoglycemia. We measured hypoglycemia-induced changes in endothelial parameters, oxidative stress markers and inflammation at baseline and after a 24-hour period in type 2 diabetic (T2DM) subjects versus age-matched controls. Case-control study: 10 T2DM and 8 control subjects. Blood glucose was reduced from 5 (90 mg/dl) to hypoglycemic levels of 2.8 mmol/L (50 mg/dl) for 1 hour by incremental hyperinsulinemic clamps using baseline and 24 hour samples. Measures of endothelial parameters, oxidative stress and inflammation at baseline and at 24-hours post hypoglycemia were performed: proteomic (Somalogic) analysis for inflammatory markers complemented by C-reactive protein (hsCRP) measurement, and proteomic markers and urinary isoprostanes for oxidative measures, together with endothelial function. Between baseline and 24 -hours after hypoglycemia, 15 of 140 inflammatory proteins differed in T2DM whilst only 1 of 140 differed in controls; all returned to baseline at 24-hours. However, elevated hsCRP levels were seen at 24-hours in T2DM (2.4 mg/L (1.2-5.4) vs. 3.9 mg/L (1.8-6.1), Baseline vs 24-hours, P < 0.05). In patients with T2DM, between baseline and 24-hour after hypoglycemia, only one of 15 oxidative stress proteins differed and this was not seen in controls. An increase (P = 0.016) from baseline (73.4 ng/mL) to 24 hours after hypoglycemia (91.7 ng/mL) was seen for urinary isoprostanes. Hypoglycemia resulted in inflammatory and oxidative stress markers being elevated in T2DM subjects but not controls 24-hours after the event.

Citing Articles

A Cross-Sectional Exploratory Study of Rat Sarcoid (Ras) Activation in Women with and Without Polycystic Ovary Syndrome.

Niinuma S, Habib H, Takemoto A, Das P, Sathyapalan T, Atkin S Cells. 2025; 14(5).

PMID: 40072105 PMC: 11898917. DOI: 10.3390/cells14050377.


Cardiovascular Risk Biomarkers in Women with and Without Polycystic Ovary Syndrome.

Nandakumar M, Das P, Sathyapalan T, Butler A, Atkin S Biomolecules. 2025; 15(1).

PMID: 39858399 PMC: 11763313. DOI: 10.3390/biom15010004.


Matrix Metalloproteinases, Tissue Inhibitors of Metalloproteinases, and Their Ratios in Women with Polycystic Ovary Syndrome and Healthy Controls.

Butler A, Nandakumar M, Sathyapalan T, Brennan E, Atkin S Int J Mol Sci. 2025; 26(1.

PMID: 39796177 PMC: 11720512. DOI: 10.3390/ijms26010321.


Hypoglycaemic stimulation of macrophage cytokine release is suppressed by AMP-activated protein kinase activation.

Zhang J, Pollard A, Pearson E, Carling D, Viollet B, Ellacott K Diabet Med. 2024; 42(3):e15456.

PMID: 39717018 PMC: 11823358. DOI: 10.1111/dme.15456.


PCSK7 levels in women with and without PCOS.

Atkin S, Butler A, Jamialahmadi T, Sahebkar A J Clin Transl Endocrinol. 2024; 38:100376.

PMID: 39691660 PMC: 11650127. DOI: 10.1016/j.jcte.2024.100376.


References
1.
Davis S, Duckworth W, Emanuele N, Hayward R, Wiitala W, Thottapurathu L . Effects of Severe Hypoglycemia on Cardiovascular Outcomes and Death in the Veterans Affairs Diabetes Trial. Diabetes Care. 2018; 42(1):157-163. PMC: 6463547. DOI: 10.2337/dc18-1144. View

2.
Kahal H, Aburima A, Spurgeon B, Wraith K, Rigby A, Sathyapalan T . Platelet function following induced hypoglycaemia in type 2 diabetes. Diabetes Metab. 2018; 44(5):431-436. DOI: 10.1016/j.diabet.2018.04.004. View

3.
Ishibashi T . Molecular hydrogen: new antioxidant and anti-inflammatory therapy for rheumatoid arthritis and related diseases. Curr Pharm Des. 2013; 19(35):6375-81. PMC: 3788323. DOI: 10.2174/13816128113199990507. View

4.
Fullard N, OReilly S . Role of innate immune system in systemic sclerosis. Semin Immunopathol. 2015; 37(5):511-7. DOI: 10.1007/s00281-015-0503-7. View

5.
Miller M, Bonds D, Gerstein H, Seaquist E, Bergenstal R, Calles-Escandon J . The effects of baseline characteristics, glycaemia treatment approach, and glycated haemoglobin concentration on the risk of severe hypoglycaemia: post hoc epidemiological analysis of the ACCORD study. BMJ. 2010; 340:b5444. PMC: 2803743. DOI: 10.1136/bmj.b5444. View